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RESEARCH ARTICLE Open Access
Phenotyping dividing cells in mouse models of
neurodegenerative basal ganglia diseases
Arthur Smardencas1, Kerelos Rizkalla1, Hyun Ah Kim1,2, Jim Massalas1, Claire O’Leary1,3, Michelle E Ehrlich4,
Günter Schütz5, Andrew J Lawrence1 and John Drago1*
Abstract
Background: Mice generated by a Cre/LoxP transgenic paradigm were used to model neurodegenerative basal
ganglia disease of which Huntington disease (HD) is the prototypical example. In HD, death occurs in striatal
projection neurons as well as cortical neurons. Cortical and striatal neurons that express the D1 dopamine receptor
(Drd1a) degenerate in HD. The contribution that death of specific neuronal cell populations makes to the HD
disease phenotype and the response of the brain to loss of defined cell subtypes is largely unknown.
Methods: Drd1a-expressing cells were targeted for cell death and three independent lines generated; a striatal-
restricted line, a cortical-restricted line and a global line in which Drd1a cells were deleted from both the striatum
and cortex. Two independent experimental approaches were used. In the first, the proliferative marker Ki-67 was
used to identify proliferating cells in eighty-week-old mice belonging to a generic global line, a global in which
Drd1a cells express green fluorescent protein (GFP-global) and in eighty-week-old mice of a cortical line. In the
second experiment, the proliferative response of four-week-old mice belonging to GFP-global and striatal lines was
assessed using the thymidine analogue BrdU. The phenotype of proliferating cells was ascertained by double
staining for BrdU and Olig2 (an oligodendrocyte marker), Iba1 (a microglial cell marker), S100β (an astroglial cell
marker), or NeuN (a neuronal cell marker).
Results: In the first study, we found that Ki-67-expressing cells were restricted to the striatal side of the lateral
ventricles. Control mice had a greater number of Ki-67+ cells than mutant mice. There was no overlap between
Ki-67 and GFP staining in control or mutant mice, suggesting that cells did not undergo cell division once they
acquired a Drd1a phenotype. In contrast, in the second study we found that BrdU+ cells were identified
throughout the cortex, striatum and periventricular region of control and mutant mice. Mutant mice from the
GFP-global line showed increased BrdU+ cells in the cortex, striatum and periventricular region relative to control.
Striatal line mutant mice had an increased number of BrdU+ cells in the striatum and periventricular region, but not
the cortex. The number of microglia, astrocytes, oligodendrocytes and neurons generated from dividing progenitors
was increased relative to control mice in most brain regions in mutant mice from the GFP-global line. In contrast,
striatal line mutant mice displayed an increase only in the number of dividing microglia in striatal and
periventricular regions.
Conclusions: Genetically programmed post-natal ablation of Drd1a-expressing neurons is associated with an
extensive proliferative response involving multiple cell lineages. The nature of the tissue response has the potential
not only to remove cellular debris but also to forge physiologically meaningful brain repair. Age related deficits in
proliferation are seen in mutant lines. A blunted endogenous reparative response may underlie the cumulative
deficits characteristic of age related neurodegeneration.
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Background
Huntington disease (HD) is characterized by progressive
degeneration and loss of neurons in the brain, particu-
larly the dopamine-responsive medium spiny neurons of
the striatum [1]. HD is an autosomal dominant condi-
tion caused by expansion of the polyglutamine repeat
sequence in the protein Huntingtin. Clinically, HD pa-
tients may present with motor disorders, cognitive defi-
cits, psychosis and anxiety disorder [2]. Mortality usually
occurs within 15–20 years of onset of symptoms.
The D1 dopamine receptor (Drd1a)-expressing cell dele-
tion mouse lines used in this study were generated by the
Cre/LoxP transgenic method and include the global (i.e.
striatal and cortical) (Drd1a/Tox × Cam Kinase IIa/Cre
[3]), the striatal restricted (Drd1a/Tox × DARPP-32/Cre
[4]), and cortical restricted (Drd1a/Tox × Emx-1/Cre) lines.
The motor and neurochemical phenotype of individual
lines depends on the molecular paradigm and target site
from which Drd1a-expressing cells have been lost [3]. In
this study, Cre recombinase-expressing transgenic mice are
crossed with transgenic mice containing the attenuated
diphtheria toxin (tox-176) gene “knocked into” the Drd1a
gene locus downstream of a floxed NEOSTOP cassette [5].
Cell death follows Cre expression and Drd1a promoter
driven tox-176 production at 1–2 weeks in the global line
[3,6] and 5 weeks in the striatal line [4]. The Emx-1 pro-
moter drives Cre expression during embryogenesis [7] and
is selective for telencephalic pyramidal cells [8].
The anatomical changes that occur in the mammalian
brain following sterile non-traumatic neuronal cell death
are not completely understood. There is evidence from
our laboratory that the density of D2 dopamine recep-
tor-expressing striatal neurons increases following the
loss of Drd1a-expressing neurons [3,5]. The response of
other cell types in the brain such as oligodendrocytes,
microglia and astrocytes remains to be defined.
The broad aim of the study was to characterize the
proliferative response following targeted tox-176 medi-
ated Drd1a cell injury. Two independent approaches
were used; one of these approaches exploits the fact
that proliferating cells express the protein Ki-67 in
their nuclei. Another approach involved administration
of the thymidine analogue 5’-bromo-2’-deoxyuridine
(BrdU) as a marker for DNA synthesis. BrdU was used
to assess proliferation in 4-week-old mice of the striatal
and green fluorescent protein (GFP)-containing global
[Drd1a-GFP/Tox × Cam Kinase IIa/Cre] lines (called
GFP-global). In these mice, double labelling of BrdU
with either NeuN (for neurons), Olig2 (to identify ma-
ture oligodendrocytes and oligodendrocyte progenitor
cells), Iba1 (for microglia) or S100β (for astrocytes) was
used to determine the quantity, distribution and pheno-
type of dividing cells in the brain. Eighty-week-old mice
of the global (both GFP-expressing and non GFP-
expressing) and cortical lines were assessed to determine
the quantity and distribution of dividing cells. Double
labelling with Ki-67 and GFP was used to determine if
dividing cells were Drd1a-expressing.
Results
BrdU analysis
Cell distribution
Controls Cells positive for BrdU were identified in con-
trol mice for the two lines examined (GFP-global and
striatal). The BrdU+ cells were distributed throughout
the motor cortex, striatum and periventricular region.
Figure 1 (A-C) and Figure 1 (G-I) are representative
photomicrographs of coronal sections showing BrdU+
cells throughout three brain regions in control mice for
GFP-global (GFP-control) and striatal lines respectively.
Cells that were positive for Iba1, Olig2, S100β and
NeuN were also present throughout the cortex, striatum
and periventricular region of control mice for both lines
(see below). Double staining showed that Iba1+/BrdU+,
Olig2+/BrdU+, S100β+/BrdU+ and NeuN+/BrdU+ cells
were present throughout all three regions.
Mutant mice BrdU+ cells were also distributed through-
out the motor cortex, striatum and periventricular region
of mutant mice belonging to the GFP-global and striatal
lines. Figure 1 (D-F) and Figure 1 (J-L) are representative
photomicrographs of coronal sections showing BrdU+
cells throughout the three regions of the mutant brain in
the GFP-global and striatal lines respectively. Cells that
were positive for Iba1, Olig2, S100β and NeuN were
also present throughout the cortex, striatum and periven-
tricular region of both mutant lines (see below), while
double staining showed that Iba1+/BrdU+, Olig2+/BrdU+,
S100β+/BrdU+ and NeuN+/BrdU+ cells were also present
throughout these regions.
Cell quantification
GFP-global line; BrdU+ cells Regional quantification of
the number of BrdU+ cells was undertaken in the GFP-
global line and GFP-control mice. A two-way ANOVA
demonstrated no significant genotype-by-bregma level
interaction in the cortex, striatum or periventricular re-
gion of GFP-control (n=4) and GFP-global (n=4) mice.
There was a main effect of genotype, on the BrdU+ cell
count in the cortex (P<0.01), striatum (P≤0.0001) and
periventricular region (P<0.01); the BrdU+ cell count
was increased in mutant relative to control mice in each
of these regions. Figure 2A shows the mean (± SEM) of
the cumulative number of BrdU+ cells for specific re-
gions - where cumulative number refers to the sum of
the BrdU+ cells from the five bregma levels (1.18, 0.62,
0.26, 0.02 and −0.46) quantified for each animal.
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GFP-global line; NeuN+/BrdU+ cells Regional quanti-
fication of the number of NeuN+/BrdU+ cells was
undertaken in the GFP-global line and GFP-control
mice. A two-way ANOVA demonstrated a significant
genotype-by-bregma level interaction (P<0.05) in the
cortex of GFP-control (n=4) and GFP-global (n=4) mice
(Figure 3A). A Bonferroni post-hoc test revealed a sig-
nificant increase in the NeuN+/BrdU+ cell count in mu-
tant relative to control mice at bregma level 0.26 mm
(P<0.01). In both the striatum (Figure 3E), and the
Figure 1 Fluorescence microscopy of dividing cells in control and mutant mice. Fluorescence photomicrographs showing BrdU+ (green)
cells in the motor cortex (A), striatum (B) and periventricular region (C) of a control mouse brain (GFP-control) of the GFP-global line. (D-F)
Fluorescence micrographs showing BrdU+ (green) cells in the motor cortex (D), striatum (E) and periventricular region (F) of a mutant mouse
brain from the GFP-global line. (G-I) Motor cortex (G), striatum (H) and periventricular region (I) of a control mouse brain of the striatal line. (J-L)
Fluorescence micrographs showing BrdU+ (green) cells in the motor cortex (J), striatum (K) and periventricular region (L) of a mutant mouse
brain from the striatal line. S denotes striatum, LSn denotes lateral septal nucleus and LV denotes lateral ventricle. Scale bar represents 70 μm.
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periventricular (Figure 3I) region of these mice there
was a main effect of genotype (both P<0.01) but no
genotype-by-bregma level interaction, indicating that the
two genotypes always differed irrespective of bregma
level. Table 1 shows the mean (± SEM) of the percentage
of BrdU+ cells that were NeuN+.
GFP-global line; Iba1+/BrdU+ cells Regional quantifi-
cation of the number of Iba1+/BrdU+ cells was under-
taken in the GFP-global line and GFP-control mice. A
two-way ANOVA demonstrated a main effect of geno-
type in the cortex, striatum and periventricular region
between control (n=4) and mutant (n=4) mice (all
P<0.01) but no genotype-by-bregma level interaction in
any region (Figure 3B, E and J). Table 1 shows the mean
(± SEM) of the percentage of BrdU+ cells that were Iba1+
per animal in all regions of the brain for both mutant and
control mice.
GFP-global line; S100β+/ BrdU+ cells Figure 4A-C de-
picts confocal photomicrographs showing S100β+ and
BrdU+ cells and an S100β+/BrdU+ double positive cell in
the cortex of a GFP-global mutant mouse brain. Regional
quantification of the number of S100β+/BrdU+ cells was
undertaken in the GFP-global line (n=4) and control mice
(n=4). A two-way ANOVA demonstrated a main effect of
genotype in the cortex (P<0.01) (Figure 3C) and periven-
tricular region (P<0.05) (Figure 3K), but not in the
striatum (Figure 3G). There was no significant genotype-
by-bregma level interaction in any region. Table 1 shows
the mean (± SEM) of the percentage of BrdU+ cells that
was S100β+ per animal in all regions of the brain for both
mutant and control mice.
GFP-global line; Olig2+/BrdU+ cells Figure 4 depicts
confocal photomicrographs of Olig2+, BrdU+ cells and
Olig2+/BrdU+ double positive cells in the striatum of a
mutant GFP-global brain. Regional quantification of the
number of Olig2+/BrdU+ cells was undertaken in the
GFP-global line (n=4) and GFP-control mice (n=4). A
two-way ANOVA demonstrated a main effect of geno-
type in the cortex (P<0.01) (Figure 3D) and striatum
(P<0.05) (Figure 3H) but not in the periventricular region
(Figure 3L). There was no significant genotype-by-bregma
level interaction in any region. Table 1 shows the mean
(± SEM) of the percentage of BrdU+ cells that were Olig2+
per animal in all regions of the brain for both mutant and
control mice.
Striatal line; BrdU+ cells Regional quantification of the
number of BrdU+ cells was undertaken in the striatal
line (n=4) and littermate control mice (n=4). A two-way
ANOVA demonstrated a main effect of genotype on the
number of BrdU+ cells in the striatum (P<0.01) and
periventricular region (P<0.05); the BrdU+ cell count
was significantly increased in mutant relative to control
mice in each region. There was no effect of genotype or
bregma level on the BrdU+ cell count in the cortex.
There was no significant genotype-by-bregma level inter-
action in any region. Figure 2B shows the mean (± SEM)
of the cumulative number of BrdU+ cells per animal in
each region of the brain for mutant and control mice.
Striatal line; NeuN+/BrdU+ cells Figure 5 represents
confocal photomicrographs showing NeuN+, BrdU+ and
a NeuN/BrdU double positive cell in the cortex of a con-
trol brain. Regional quantification of the number of
Figure 2 Regional quantification of dividing cells in GFP-control and GFP-global mutant mice. Bar graphs showing the number of BrdU+
cells in each brain region of control (GFP-control) and mutant mice from the GFP-global (A), and control and striatal lines (B). Each bar represents
the mean (± SEM) of the cumulative number of BrdU+ cells per mutant (n=4) or control (n=4) as determined from five coronal sections per
mouse obtained between 1.18 mm to −0.46 mm from bregma. Asterisks refer to the results of the 2-way ANOVA using the original cell counts.
There was a main effect of genotype in the form of a greater number of BrdU+ cells in the cortex (**P<0.01), striatum (***P≤0.0001) and periven-
tricular region (**P<0.01) of the GFP-global relative to GFP-control lines. There was a main effect of genotype in the form of a greater number of
BrdU+ cells in the striatum (*P<0.05) and periventricular region (*P<0.05) of striatal line relative to control mice.
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Figure 3 (See legend on next page.)
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NeuN+/BrdU+ cells was undertaken in the striatal line
and control mice. A two-way ANOVA demonstrated no
significant genotype-by-bregma level interaction in the
cortex (Figure 6A), striatum (Figure 6E) or periventricu-
lar (Figure 6I) region of control (n=4) and mutant (n=4)
mice. Furthermore, there was no main effect of genotype
in any region. Table 2 shows the mean (± SEM) of the
percentage of BrdU+ cells that were NeuN+ per animal
in all regions of the brain for mutant and control mice.
Striatal line; Iba1+/BrdU+ cells Figure 5(D-F) repre-
sents confocal photomicrographs showing Iba1+, BrdU+
cells and an Iba1/BrdU double positive cell in the
striatum of a striatal-line mutant brain. Regional quanti-
fication of the number of Iba1+/BrdU+ cells was under-
taken in the striatal line (n=4) and control mice (n=4). A
two-way ANOVA demonstrated a main effect of geno-
type in the striatum (Figure 6F) and periventricular re-
gion (Figure 6J) (both P<0.001), but no effect in the
cortex (Figure 6B). There was no significant genotype-
by-bregma level interaction in any region. Table 2 shows
the mean (± SEM) of the percentage of BrdU+ cells that
were Iba1+ per animal in all regions of the brain for
both mutant and control mice.
Striatal line; S100β+/BrdU+ cells Regional quantifica-
tion of the number of S100β+/BrdU+ cells was under-
taken in the striatal line and control mice. A two-way
ANOVA demonstrated no significant genotype-by-
bregma level interaction in the cortex, striatum or peri-
ventricular region of control (n=4) and mutant (n=4)
mice. Furthermore, there was no main effect of genotype
in any region. Table 2 shows the mean (± SEM) of the
percentage of BrdU+ cells that were S100β+ per animal
in all regions of the brain for mutant and control mice.
Striatal line; Olig2+/BrdU+ cells Regional quantifica-
tion of the number of Olig2+/BrdU+ cells was under-
taken in the striatal line and control mice. A two-way
ANOVA demonstrated no significant genotype-by-
bregma level interaction in the cortex, striatum or peri-
ventricular region of control (n=4) and mutant (n=4)
mice. There was no effect of genotype on the number of
Olig2+/BrdU+ cells in any region (Figure 6D, H and L).
Table 2 shows the mean (± SEM) of the percentage of
BrdU+ cells that were Olig2+ per animal in all regions
of the brain.
Summary of the BrdU-co-labelling analyses
The young mutant GFP-global and striatal lines demon-
strated a statistically significant increase in BrdU+ cell
numbers relative to control mice. There was a difference
between the two mutant lines in the regional distribu-
tion of dividing cells. The GFP-global line displayed an
increase in the number of BrdU+ cells in the cortex,
striatum and periventricular region. In contrast, up-
regulated BrdU+ cell numbers were restricted to the stri-
atum and periventricular region in the striatal ablation
line. Significant increases in double-labelled cell
numbers were observed in mutant relative to control
mice; however, a difference was observed between
the two mutant lines. GFP-global line mutant mice
(See figure on previous page.)
Figure 3 Regional quantification of neuronal, microglial, astroglial and oligodendroglial lineage cells derived from dividing
progenitors in GFP-control and GFP-global mutant mice. Graphs showing the number of double-positive NeuN+/BrdU+, Iba1+/BrdU+, S100β+/
BrdU+ and Olig2+/BrdU+ cells at specific sites relative to bregma in the M1 motor cortex (A-D), striatum (E-H) and periventricular (I-L) regions of the
brain of mice belonging to the GFP-global line and GFP-control mice injected for 2 weeks with BrdU+ at 4 weeks of age and killed at age 8 weeks of
age for analysis. Each point represents the mean ± SEM as determined for each bregma level in mutant (n=4) and control (n=4) mice. There was a
greater number of NeuN+/BrdU+ cells in GFP-global mutant relative to control mice measured at 0.26mm from bregma (**P<0.01) as determined by a
Bonferroni post-hoc test. There was also a significant increase in the number of NeuN+/BrdU+ cells in the striatum (P< 0.01) and periventricular regions
(P< 0.01), Iba1+/BrdU+ cells in all three regions (all P< 0.01), S100β+/BrdU+ cells in the cortex (P< 0.01) and periventricular regions (P< 0.01) and Olig2
+/BrdU+ cells in the cortex (P< 0.01) and striatum (P< 0.05) in GFP-global mutant relative to control mice.
Table 1 The mean (± SEM) of the percentage of BrdU+ cells that are Iba1+, S100β+, Olig2+ and NeuN+ per animal in
the defined regions of the brain of GFP-global mutant (n=4) and GFP-control (n=4) mice
Motor Cortex Striatum Periventricular Region
Mutant Control Mutant Control Mutant Control
Iba1+ 23.2 ± 7.9 0.4 ± 0.4 37.7 ± 5.6 12.0 ± 6.3 22.5 ± 2.3 6.8 ± 1.4
S100β+ 18.5 ± 4.9 16.9 ± 4.2 1.8 ± 0.7 2.7 ± 0.5 2.7 ± 0.1 2.5 ± 0.9
Olig2+ 49.8 ± 9.8 78.3 ± 1.1 17.3 ± 1.4 58.2 ± 11.3 21.4 ± 2.9 26.0 ± 3.9
NeuN+ 7.8 ± 0.9 9.2 ± 2.1 2.2 ± 0.2 1.5 ± 0.5 2.9 ± 0.8 1.7 ± 0.7
Marker-negative* 0.7 0 41.0 25.6 50.5 63.0
* refers to the percentage of BrdU+ cells that did not label with any of the four antibodies. This was calculated as the difference between the sum of the
percentages for the panel of four antibodies and 100. This calculation assumes that the selected lineage specific antibodies are indeed specific and BrdU positive
cells in this study co-express only one lineage marker.
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displayed increased NeuN+/BrdU+, Iba1+/BrdU+,
S100β+/BrdU+ and Olig2+/BrdU+ cell numbers in
at least two of the three regions of the brain, in-
cluding the cortex whereas striatal line mutant mice
only displayed an increase in the Iba1+/BrdU+ cell
numbers with this increase being confined to the
striatum and periventricular region.
Ki-67 analysis
Cell distribution
Immunohistochemical staining for Ki-67+ cells revealed
an irregular distribution pattern throughout the periven-
tricular region lining the lateral ventricles in littermate
control mice. Ki-67+ cells were identified only on the
striatal side of the ventricles. Figure 7 shows photomi-
crographs of a GFP-control brain. The Ki-67+ cells line
the lateral ventricles (Figure 7A). The GFP+ cells were
distributed throughout the entire striatum (Figure 7B).
Double staining showed that there were no cells posi-
tive for both Ki-67 and GFP (Figures 7C and 7D). Ki-67
+ cells were also distributed in an irregular pattern
throughout the striatal side of the periventricular re-
gion lining the lateral ventricles in mutant global, GFP-
global and cortical lines. Figure 7(E-H) depicts a photo-
micrograph of a mutant brain from a GFP-global line.
The Ki-67+ cells line the lateral ventricles (Figure 7E).
GFP+ cells were distributed throughout the entire stri-
atum (Figure 7F). Double staining showed that there
were no cells positive for both Ki-67 and GFP (Fig-
ures 7G and 7H).
Cell quantification; GFP-global line
A two-way ANOVA demonstrated a significant (P<0.01)
genotype-by-bregma level interaction in the periven-
tricular region of control (n=4) and mutant (n=4) mice.
A Bonferroni post-hoc test confirmed a significant re-
duction in the Ki-67+ cell count in mutant relative to
control mice at bregma levels 1.18 mm (P<0.01), 0.50
mm (P<0.05) and 0.26 mm (P<0.01). Figure 8A shows
Figure 4 Fluorescence microscopy of astroglial and oligodendroglial lineage cells derived from dividing cells. Panel A is a confocal
photomicrograph that shows an S100β+ (red) astroglial cell in the cortex of a GFP-global line mouse brain. Panel B is a confocal photomicro-
graph that shows BrdU+ (green) cells in the same field. Panel C represents the merging of panels A and B and indicates the cell (arrow) is a
double positive S100β+/BrdU+ (yellow) astroglial cell, which has undergone cell division. Scale bar in panels A, B and C represents 15 μm. Panel
D is a confocal photomicrograph showing Olig2+ (red) cells in the striatum of a mutant mouse brain from the GFP-global line. Panel E is a
confocal photomicrograph that shows BrdU+ (green) cells in the same field. Panel F represents the merging of panels D and E and indicates that
two cells (arrows) are Olig2+/BrdU+ (yellow) and are therefore oligodendroglial lineage cells, which have undergone cell division. Scale bar in
panels D, E and F represents 12 μm.
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the mean (± SEM) of the Ki-67+ cell count at each
bregma level for control and mutant mice.
Cell quantification; global line
A two-way ANOVA demonstrated a significant (P<0.05)
genotype-by-bregma level interaction in the periven-
tricular region of control (n=4) and mutant (n=4) mice.
A Bonferroni post-hoc test showed that there was a sig-
nificant reduction in the Ki-67+ cell count in mutant
relative to control mice at bregma level of 1.18 mm
(P<0.01). Figure 8B shows the mean (± SEM) of the
Ki-67+ cell count at each bregma level for the control
and mutant mice.
Cell quantification; cortical line
A two-way ANOVA demonstrated a significant (P<0.05)
genotype-by-bregma level interaction in the periventricu-
lar region of control (n=4) and mutant (n=4) mice. A
Bonferroni post-hoc test showed that there was a significant
reduction in the Ki-67+ cell count in mutant relative to
control mice at bregma level 1.18 mm (P<0.01). Figure 8B
shows the mean (± SEM) of the Ki-67+ cell count at each
bregma level for control and mutant mice.
Discussion
We observed a marked increase of BrdU+ cell numbers in
young mutant mice relative to control mice in the GFP-
global and striatal lines. We saw an increase in the num-
ber of BrdU+ cells in brain regions, predicted on the basis
of the Cre activator line used, to sustain maximal levels of
tox-176-mediated death of Drd1a-expressing cells. These
regions are the cortex and striatum (including the periven-
tricular region) of GFP-global line mutant mice, and the
striatum (including the periventricular region) of striatal
line mutant mice. As BrdU is a marker of DNA synthesis
[9], our study suggests that the brain produces new, divi-
ding cells in an attempt to compensate for the regionally
restricted tox-176-mediated loss of Drd1a-expressing cells.
A limitation of BrdU as a proliferative marker is that it not
only incorporates into nascent DNA during S phase of the
Figure 5 Fluorescence microscopy of neuronal and microglial cells derived from dividing progenitors. Panel A is a confocal photomicro-
graph that shows NeuN+ (red) cells in the cortex of a control mouse brain for the striatal line. Panel B is a confocal photomicrograph that shows
a BrdU+ (green) cell in the same field. Panel C represents the merging of panels A and B, and indicates that the cell (arrow) is NeuN+/BrdU+
(yellow) and therefore represents a neuron derived from a dividing progenitor cell. Scale bar in panels A, B and C represents 12 μm. Panel D is a
confocal photomicrograph that shows Iba1+ (red) cells in the striatum of a mutant mouse brain from the striatal line. Panel E is a confocal
photomicrograph that shows BrdU+ (green) cells in the same field. Panel F represents the merging of panels D and E and indicates that one cell
(arrow) is Iba1+/BrdU+ (yellow) and therefore represents a microglial cell derived from a cell that has undergone cell division. Scale bar in panels
D, E and F represents 15 μm.
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mitotic cycle but it may also integrate into cellular DNA
during DNA repair and in the context of apoptosis.
Although both DNA repair and apoptosis represent theo-
retical possibilities, this would not explain the uniform
nuclear staining, the number of BrdU+ doublets, and
more importantly the large number of BrdU positive cells
(~ 720 cells/5 sections-see Figure 2A and Figure 1D-F)
seen in global ablation mutant mice. Furthermore, TUNEL
staining undertaken in global ablation mutant mice [3]
aged between 2 and 9 weeks identified very few TUNEL
positive cells. In addition, TUNEL-positive cells were not
seen in the cortex. A small number of TUNEL-positive
cells (approximately five/section) were seen in the hippo-
campus and thalamus of a two-week old mutant, brain
regions known to express the Drd1a-receptor. The degree
of striatal volume loss is no different in the striatal-
restricted line and the mechanism of cell death is the same
(i.e. tox-176 mediated cell death) and so there is no reason
to believe that apoptosis would be any more prominent in
this line. Taken together, these data suggest that it is highly
improbable that the large number of BrdU-positive cells
seen in our mutant lines represent anything other than
active cell turnover in response to the targeted attenuated
diphtheria-toxin mediated cell death of Drd1a-expressing
cells.
There was also a marked increase in the number of
dividing microglia/macrophages in young mutant mice
belonging to the GFP-global and striatal lines. This in-
crease was confined to areas of the brain targeted by
tox-176-mediated Drd1a-expressing cell death. The robust
regional increase in the number of newly synthesized
microglia is likely to reflect an inflammatory response
elicited by the primary death of Drd1a-expressing cells.
Microglia, with their elaborate processes, respond to the
presence of necrotic tissue by phagocytosing and remo-
ving debris [10-13]. Microglia have other roles including
modulation of synaptogenesis and neurogenesis [14],
processes that may be particularly relevant in our models
of neurodegeneration.
There was a marked enhancement of the number of
dividing astrocytes in the cortex and periventricular re-
gion of young mutant mice belonging to the GFP-global
line although, no such enhancement was observed in
mutant mice belonging to the striatal line. Astrocytes
are known to participate in long-term brain repair and
maintenance [15-18]. Their functions include the release
of trophic factors that influence neurite growth, and the
formation of a glial scar through the process of reactive
gliosis. The survival of neurons is known to be depen-
dent on astrocyte functions such as free radical scaven-
ging and glutamate uptake/release.
In order to determine why a pleiotropic proliferative/
repair response appears to have been activated in mutant
mice from the GFP-global line but not from striatal line
mutant mice, it is worthwhile comparing the time of on-
set of death of Drd1a-expressing cells in each line. The
GFP-global line is known to undergo death of Drd1a-
expressing cells at an earlier stage than the striatal line.
The death of these cells commences at about 1–2 weeks
of age in the GFP-global line, following Cre activation
[3,6], and 5 weeks of age in the striatal line [4]. Our
GFP-global mutant and GFP-control mice, therefore,
had been subjected to several weeks of cell death prior
to the commencement of the BrdU injection regime at 4
Table 2 The mean (± SEM) of the percentage of BrdU+ cells that are also Iba1+, S100β+, Olig2+ and NeuN+ per animal
in defined brain regions of the brain of striatal mutant (n=4) and control (n=4) mice
Motor Cortex Striatum Periventricular Region
Mutant Control Mutant Control Mutant Control
Iba1+ 1.8 ± 1.8 0.9 ± 0.7 19.8 ± 1. 9 0.8 ± 0.5 18.8 ± 2.4 8.5 ± 0.7
S100β+ 22.1 ± 1.9 21.6 ± 1.9 3.7 ± 2.0 13.3 ± 2.5 5.9 ± 1.5 8.1 ± 1.3
Olig2+ 74.8 ± 2.1 70.9 ± 3.2 46.1 ± 8.4 72.6 ± 4.8 32.4 ± 3.5 31.3 ± 5.8
NeuN+ 14.7 ± 1.3 14.3 ± 6.1 3.2 ± 0.2 8.1 ± 1.9 3.5 ± 0.9 2.5 ± 0.5
Marker-negative* 0 0 27.2 5.2 39.4 49.6
* refers to the percentage of BrdU+ cells that did not label with any of the four antibodies. This was calculated as the difference between the sum of the
percentages for the panel of four antibodies and 100. This calculation assumes that the selected lineage specific antibodies are indeed specific and BrdU positive
cells in this study co-express only one lineage marker.
(See figure on previous page.)
Figure 6 Regional quantification of neuronal, microglial, astroglial, and oligodendroglial cells derived from dividing progenitors in
control and striatal line mutant mice. Graphs showing the number of double-positive NeuN+/BrdU+, Iba1+/BrdU+, S100β+/BrdU+ and Olig2
+/BrdU+ cells at specific sites relative to bregma in the M1 motor cortex (A-D), striatum (E-H) and periventricular (I-L) regions of the brain of
mice belonging to the striatal line and control mice injected for 2 weeks with BrdU+ at 4 weeks of age and killed at age 8 weeks. There was a
significant increase in the number of Iba1+/BrdU+ cells in the striatum and periventricular regions (both P< 0.001) in striatal mutant relative to
control mice.
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weeks of age. In contrast, the death of Drd1a-expressing
cells would not have commenced in striatal line mutant
mice until 5 weeks of age, which is at a point halfway
through the 2-week BrdU injection regime administered
to these animals commencing at 4 weeks of age. The
death of these cells would, therefore, have been relatively
advanced in GFP-global as compared with striatal mu-
tant mice. It is conceivable that the enhanced number of
dividing astrocytes in the mutant mice belonging to the
GFP-global line reflected the comparatively early time of
death of the Drd1a-expressing cells in this line, which
allowed a greater time for a proliferative astrocyte re-
sponse to develop.
The presence of BrdU+/NeuN+ double positive cells
in the cortex, striatum and periventricular regions of
young control and mutant mice belonging to the GFP-
global and striatal lines confirmed that neurons were
generated from dividing cells in the post-natal period in
all lines. The number of BrdU+ neurons was increased
relative to control mice in the striatum and periventricu-
lar region of GFP-global mutant mice but not in striatal
line mutant mice. These results are consistent with pub-
lished reports indicating that while constitutive neuro-
genesis occurs throughout the post-natal brain [19],
albeit at low levels [20-22], enhanced neurogenesis in re-
sponse to the loss of Drd1a-expressing cells in our study
was restricted to the GFP-global line. This result would
appear to correlate with a comparatively subtle orofacial
phenotype observed in global line mutant as compared
with striatal line mutant mice [23]. A caveat for the
observed difference between the GFP-global and striatal
lines may be that the temporal profile of Cre-expression
and therefore tox-176 mediated death of Drd1a-express-
ing cells in the striatal line was incompatible with a fully
evolved proliferative response to become manifest within
the time frame of the study design.
The generated NeuN+ cells are likely to do one
of two things. First, they may differentiate into Drd1a-
expressing striatal medium spiny GABAergic projection
neurons or Drd1a-expressing cortical glutamatergic
corticostriatal projection thereby replacing cells that are
killed by tox-176 expression. Owing to their molecular
signature, these cells are likely to ultimately suffer the
same fate as the cells they replace. Second, the generated
cells may differentiate into Drd2-expressing striatal pro-
jection neurons, non-Drd1a-expressing striatal interneu-
rons or cortical non-Drd1a-expressing pyramidal cells.
Expansion of the non-Drd1a-expressing compartments
would thereby functionally compensate for the primary
loss of Drd1a-expressing cells. We have evidence for up-
regulated D2-compartment expression for the global-
ablation mutant mice [3,24,25] lending support to this
compensation hypothesis. An experiment quantifying
BrdU+ cells co-expressing Drd2 in young BrdU injected
global-mutant mice on a D2-GFP reporter background
would directly address this question.
The number of dividing Olig2+ cells was increased in
the cortex and striatum of young mutant mice from the
GFP-global line but not young mutant mice from the
striatal line. Olig2 is a transcription factor found in cells
that differentiate into oligodendrocytes [26]. The differ-
entiated cells supply the axons of neurons with their
myelin coats, an important function that correlates
with neurogenesis and neural maturation/remodelling as
newly generated axons require myelin [27]. It is concei-
vable that our finding of enhanced numbers of dividing
Olig2+ cells in the mutants from the GFP-global line
reflects the necessary partnership between the gene-
ration of new oligodendrocytes and the generation of
new neurons, neuronal processes and neuronal intercon-
nections in these animals.
The expression of Olig2 is not confined to the differ-
entiation path that produces mature oligodendrocytes.
Olig2+ cells may also differentiate into neurons [28,29],
ependymal cells [30] and astrocytes [31,32]. It is concei-
vable that dividing Olig2+ cells in the cortex and stri-
atum of the mutants from the GFP-global line may
ultimately differentiate into neurons or astrocytes in
these regions of the brain, and thus contribute to the ob-
served up-regulation of these types of cells in response
to tox-176-mediated death of Drd1a-expressing cells.
In the cortex of control and mutant mice for the GFP-
global and striatal lines, virtually 100% of the dividing
cells were identified on the basis of marker expression,
as microglia, astrocytes, neurons or oligodendrocytes.
However, in the striatum and to a greater extent in the
periventricular region, a large percentage of the dividing
cells were negative for all markers suggesting that an
(See figure on previous page.)
Figure 7 Fluorescence photomicrographs showing Ki-67+ (red) and GFP+ (green) cells in GFP-control and GFP-global lines analysed at
80 weeks post-natal. In GFP-control mice, (A) Ki-67+ cells (arrow) are located along the striatal side of the lateral ventricle and (B) GFP staining
shows Drd1a-expressing cells and dense neuropil distributed throughout the striatum. There is no overlap between Ki-67+ (white arrow) and
GFP+ (blue arrow) cells (panels C and D). Scale bar represents 150 μm in panels A, B, C, and 50 μm in panel D. In GFP-global line mice, Ki-67+
cells (arrow) are distributed along the striatal side of the lateral ventricle (E) and GFP staining shows Drd1a-expressing cells and neuropil
distributed throughout the striatum (F). As for GFP-control mice, no overlap of Ki-67+ (white arrow) and GFP+ (blue arrow) cells (G and H) was
observed in GFP-global line mice. S denotes striatum and LV denotes lateral ventricle. Scale bar represents 150μm in panels E, F, G, and 50μm in
panel F.
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increasing proportion of cells were progenitor cells that
remained uncommitted to any particular lineage. Judging
from the distribution profile of identifiable dividing
cells in our study, it would appear that new cells that
were manufactured in the sub-ventricular zone of the
periventricular region divided and differentiated as they
migrated through the striatum and to the cortex. By the
time they reached the cortex, differentiation was more or
less complete, and thus based on co-expression of lineage
specific markers, all BrdU+ cells were readily assigned a
Figure 8 Regional quantification of Ki67+ cells in GFP-control, GFP-global, global-mutant, cortical-mutant and control lines. (A) The
distribution of Ki-67+ cells relative to bregma on the striatal side of the periventricular region in the brain of GFP-global mutant and GFP-control
mice analysed at 80 weeks post-natal. Each point represents the mean ± SEM at a specific distance from bregma in mutant (n=4) and control
(n=4) mice. There were fewer Ki-67+ cells in mutant mice, the difference being significant at the three most cranially located points of 1.18
(**P<0.01), 0.50 (*P<0.05) and 0.26 (**P<0.01) mm from bregma as determined by a Bonferroni post-hoc test. (B) The distribution of Ki-67+ cells
relative to bregma in the striatal side of the periventricular region of the brain of mutant mice belonging to the global and cortical lines and
global line littermate age matched control mice. Each point represents the mean ± SEM as determined for each distance from bregma in mutant
(n=4) and control (n=4) mice. In each line, there were fewer Ki-67+ cells in mutant relative to control mice with the difference being significant at
1.18 mm from bregma (**P<0.01) as determined by a Bonferroni post-hoc test.
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phenotype. We propose that some of the phenotype nega-
tive BrdU+ cells in the striatum and periventricular region
may consist of immature neurons that are yet to express
NeuN. Validation of this idea would require further exper-
iments such as; a time course analysis of the regional dis-
tribution of BrdU positive cells after BrdU-pulsing,
staining for co-expression of BrdU-positive cells with
markers seen in migrating and differentiating neuronal pre-
cursors such as doublecortin and PSA-NCAM [33], or an
analysis of Ki67-positive cell distribution in a younger mutant
cohort. Neurogenesis occurs in the adult mammalian brain,
including that of humans [34,35]. Neurogenesis is known to
occur in the sub-ventricular zone [36,37], the region of the
brain that lines the lateral ventricular cavity. It is also possible
that rather than originating from periventricular zone stem
cells, NeuN/BrdU double positive cells could originate in situ
from quiescent stem cells found in the striatum.
Young global and striatal ablation mutants assessed
using BrdU as a proliferative marker displayed a marked
up-regulation in the number of dividing cells. In contrast,
older mice of the global and cortical mutant lines showed
markedly reduced Ki-67+ cell numbers when compared to
control mice. Experimental confirmation of this finding
would involve a direct comparison of the proliferative pro-
file in 4 week and 80 weeks old mice using established Ki-
67 immunofluorescence and BrdU protocols. Our finding
of reduced Ki-67+ cell numbers in older mutant lines ap-
pears to be at odds with some published studies, which
underscore an increased proliferative response in humans
with HD and rodent HD models [38,39], although other
studies in HD models have identified region specific im-
paired neurogenesis. Decreased hippocampal dentate gyrus
neurogenesis was seen in the transgenic YAC128 model
[40]. Olfactory bulb neurogenesis was down-regulated in
the hippocampus [41] and olfactory bulb [42] of R6/2
transgenic HD mice and striatal cell neurogenesis was im-
paired in a HD knock-in line [43]. However, it is important
to note the age (i.e. 80 weeks) of the mice used in this
study. The comparative difference between mutant and
control mice may relate to the advanced age of the mice
used in this study. We postulate that the aged mutant
brain is unable to mount an effective proliferative response
[44] owing to paradigm driven increased proliferative de-
mand in early adulthood and ultimate stem cell pool deple-
tion. There is ample evidence for age-related stem cell
depletion in the CNS [19,45]. Although neural stem cells
isolated from the subventricular zone of aged animals are
able to divide and differentiate into functional neurons and
other neural lineages, they do so with reduced efficiency
[45]. A large number of factors may impact on this age-
related decline in functional stem cell depletion such as
changes in the neurogenic niche and neural progenitor cell
specific variables such as altered gene transcription and te-
lomerase activity [19].
Another explanation for the reduced number of Ki-67+
cells in the mutant mice is the possibility that the prolifera-
tive pool contains Drd1a-expressing cells. In this scenario,
neural precursor cells that express Drd1a in a transient
fashion undergo tox-176-mediated death before they have
an opportunity to enter a permissive phase of the cycle and
express Ki-67. Cre expression would occur only if the
CamKIIa or EMX1 transgenes are expressed in neural pre-
cursor cells of the global and cortical lines respectively. If
Drd1a is transiently expressed in these cells, then Cre must
be expressed before Drd1a to enable Cre-mediated recom-
bination of LoxP sites and Drd1a promoter-driven produc-
tion of tox-176. If neural progenitor cells express Drd1a,
death of these cells will ensue resulting in the absence of a
proliferative response in this paradigm and the uniformly
low Ki-67+ cell numbers seen in the mutant mice. There
are two strong counter arguments. The first is that we did
not identify any GFP/Ki-67 double positive cells in GFP-
control mice and the second is that the BrdU data from
young mice show a clear increase in proliferative response
in mutant mice that are designed to shed Drd1a-expressing
cells at the time of Drd1a receptor expression.
A further possibility is that the difference in Ki-67+
cell numbers between mutant and control mice in the
rostral striatum is not an indication of a decrease in pro-
liferation in the mutant mice, but, rather reflects an
increase in migration and terminal differentiation of pro-
liferating cells in response to the molecular pathology in
mutant mice. It may be the case that there is, indeed, an
increase in proliferation in mutant mice but that the
proliferating cells are also differentiating and migrating
from the periventricular region/medial striatum towards
areas of high cell death density. If this were the case,
and considering that Ki-67 is only a marker for early cell
division [46], these differentiating and migrating cells
would not be labelled with Ki-67. This is an unlikely
explanation given the BrdU data indicate a gradient of
phenotype-negative cells maximal in the periventricular
region.
Conclusion
We used exogenous (BrdU) and endogenous (Ki-67)
markers of cell proliferation to determine the profile
(distribution and quantity) of dividing cells in young
(4-8-weeks of age) and old (80-weeks of age) mouse
models of basal ganglia diseases. In terms of the young
mice, we found that mutants from the GFP-global line
have a greater number of newly generated cells than con-
trol mice in the relevant brain regions. Mutant mice from
the striatal line have a greater number of dividing micro-
glia than control mice but there is no increase in the
number of newly generated neurons, oligodendrocytes
or astrocytes. We have, therefore, demonstrated that
genetically programmed non-traumatic and non-infectious
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targeted deletion of Drd1a-expressing cells in the post-
natal brain provokes a proliferative response that involves a
large number of cell lineages. Paradoxically, the number of
dividing cells lining the lateral ventricles-as defined by
Ki-69 expression-is reduced in older mutant mice belong-
ing to global and cortical lines. We postulate that this may
relate to stem cell pool depletion.
Methods
Mouse lines
All mice were housed 2–5 per cage with food and water
available ad libitum in a temperature-controlled environ-
ment with a 12 hours (h) light/dark cycle. The Howard
Florey Institute animal ethics committee approved all
experiments.
GFP-global line
CD1-backcrossed heterozygous mice containing the
silenced tox-176 gene [5] were mated with Drd1a/
GFP mice from the GENSAT BAC Transgenic Project
[47]. Offspring carrying both the Drd1a-GFP trans-
gene and the silenced tox-176 gene were then mated
with a heterozygous C57BL/6JArc-backcrossed Cam
Kinase IIa promoter driven Cre transgenic line [6].
GFP-global mutant mice were defined as triple trans-
genic (Drd1a-GFP/Cam Kinase IIa/Tox) whereas GFP-
control mice were littermates that were transgenic for
the Drd1a-GFP gene alone.
Global line
CD1-backcrossed heterozygous mice containing the si-
lenced tox-176 gene [5] were mated with a heterozygous
C57BL/6JArc-backcrossed Cam Kinase IIa promoter
driven Cre transgenic line [6]. Mutant mice were hetero-
zygous for both transgenes. Littermates that were not trans-
genic for either transgene were defined as control mice.
Cortical line
CD1-backcrossed heterozygous mice containing the
silenced tox-176 gene [5] were mated with a hetero-
zygous C57BL/6JArc-backcrossed EMX1 promoter
driven Cre transgenic line [48]. Cortical line mutant
mice were heterozygous for both transgenes. Wild
type mice from the Drd1a/Tox × Cam Kinase IIa/Cre
mouse cohort were used as littermate controls.
Striatal line
CD1-backcrossed heterozygous mice containing
the silenced tox-176 gene [5] were mated with a
heterozygous C57BL/6JArc-backcrossed DARPP-32
promoter-driven Cre transgenic line [4]. Mutant mice
were heterozygous for both transgenes. Control mice
were littermates that were not transgenic for either
transgene.
BrdU injections
Four-week old female mice of the striatal (n=4 mutants,
n=4 controls) and GFP-containing global (n=4 mutants,
n=4 controls) lines were injected intraperitoneally with
BrdU (50 mg/kg). Each animal was injected twice daily,
8 h apart, for 2 weeks. Following the last injection, ani-
mals were returned to their cages and a further period
of two weeks allowed to elapse before the animals were
killed with an injection of 0.2 mls of a 1:4 dilution of
Lethobarb (Virbac, Australia Limited) in normal saline
and then perfused transcardially with 0.1M phosphate
buffered saline (PBS) containing heparin (1,000 U/kg;
37°C) followed by an ice-cold mixture consisting of 4%
paraformaldehyde containing 7% picric acid diluted in
0.1M PBS (pH 7.4). and the brains removed for BrdU
analysis using immunohistochemistry. A number of pub-
lished BrdU injection protocols are available [49] [50]
[51]. Single injections are used if the aim is to precisely
date cell birth. This was not a requirement of our study.
Indeed, we chose a protocol involving multiple BrdU in-
jections, as we wanted to ensure adequate labeling of
many cells undergoing cell division over an extended
period of time. We were concerned firstly, about the in-
herently low rate of cell turnover in tissues such as the
striatum and cortex, and secondly that transient expres-
sion of Drd1a in progenitor cells may compromise cell
viability and further reduce the number of BrdU+ cells
given the evidence for a role of D1-like receptors activa-
tion on the division of striatal progenitor cells [52].
Ki-67 analysis
Eighty-week old mice of the global (n=4 mutants, n=4
controls), GFP-global (n=4 mutants, n=4 controls) and
cortical (n=4 mutants, n=4 controls) lines were killed
with an injection of 0.2 mls of a 1:4 dilution of
Lethobarb (Virbac, Australia Limited) in normal sa-
line and then perfused transcardially with 0.1M PBS
containing heparin (1,000 U/kg; 37°C) followed by an
ice-cold mixture consisting of 4% paraformaldehyde
containing 7% picric acid diluted in 0.1M PBS (pH 7.4).
and the brains removed for Ki-67 analysis using immu-
nohistochemistry.
Tissue processing
Following tissue fixation, brains were removed and
immersed in the same fixative solution for 90 min before
being transferred to 10% sucrose and stored for a further
96 h at 4°C. Brains were subsequently frozen using CO2
(BOC Gases).
Frozen brains were sectioned coronally (14 μm) using
a cryostat (Leica CM 1850). Consecutive sections be-
tween bregma 1.18 mm and −0.46 mm were collected
onto chrome alum-gelatin-coated glass slides, air dried,
and stored at −20°C. The distances from bregma [53],
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which spanned the striatum, were determined using the
corpus callosum, anterior commissure and hippocampus
as reference points. In the case of 80-week-old mice,
sections were selected from 7 levels: 1.18, 0.50, 0.26,
0.14, -0.10, -0.22 and −0.46 mm from bregma. In the
case of 4-week-old mice, sections were selected from 5
levels: 1.18, 0.62, 0.26, 0.02 and −0.46 mm from bregma.
Immunohistochemistry
Primary antibodies included rabbit anti-Ki-67 (1/200;
Thermo Scientific, USA) for dividing cells expressing
Ki-67, rat anti-BrdU (1/200; Novus Biologicals, USA)
for dividing cells incorporating BrdU, chicken anti-GFP (1/
1000; Sapphire Bioscience, Australia) for GFP-containing
neurons, rabbit anti-Olig2 (at a dilution of 1/200) for oligo-
dendrocytes, rabbit anti-Iba1 (1/200; Wako, Japan) for
microglia and macrophages, rabbit anti-S100β (1/1,500;
Abcam, USA) for astrocytes, and mouse anti-NeuN (1/500;
Millipore, USA) for neurons. Secondary antibodies included
goat anti-rabbit IgG (1/200; Alexa Fluor 594, Invitrogen,
USA), goat anti-rat IgG (1/200; Alexa Fluor 488, Invitrogen,
USA), goat anti-chicken IgG (1/200; Alexa Fluor 488,
Invitrogen, USA) and biotinylated horse anti-mouse IgG
(1/200; Vector) linked to streptavidin-549 (1/200;
Jackson).
Double labelling using rat anti-BrdU and rabbit-derived
antibodies
Sections were double-labelled over a two-day period
using a rat anti-BrdU and a selected rabbit-derived anti-
body against Olig2, Iba1 or S100β. On the first day, sec-
tions on slides were placed in 0.1M PBS for 10 min and
then immersed in a solution containing a 1:1 volume ra-
tio of 0.1M PBS and formamide. Following incubation at
65°C for 2 h, sections were rinsed three times for 5 min
in O.1M PBS. A solution of 2 M hydrochloric acid was
added and incubated at 37°C for 30 min and then sec-
tions rinsed in 0.1M PBS. A solution of 0.1 M sodium
borate was then added to each section and incubated at
room temperature for 15 min then rinsed in 0.1M PBS.
Primary antibodies were diluted in a solution consis-
ting of 0.1M PBS containing 10% goat serum and 0.4%
triton-X100. The primary antibody mix was added to
each section and the sections placed in a humidified
box, incubated overnight at room temperature and then
rinsed in 0.1M PBS. 0.1M PBS containing 10% goat
serum and 0.4% triton-X100 was then added to each sec-
tion for 15 min at room temperature. Sections were then
covered with goat anti-rat IgG and goat anti-rabbit IgG
secondary antibodies diluted in 0.1M PBS containing
10% goat serum and 0.4% triton-X100 and incubated for
3 h at room temperature. Sections were then rinsed in
0.1M PBS (3 × 10 min), cover slipped with fluorescent
mounting medium and allowed to dry.
Double labelling using rat anti-BrdU and mouse anti-NeuN
The staining protocol required the following modification in
the case of double labelling using rat anti-BrdU and mouse
anti-NeuN. 0.1M PBS containing 10% goat serum, 10% horse
serum and 0.4% triton-X100 was used to dilute all primary
and secondary antibodies and streptavidin-549. The second-
ary antibody for mouse anti-NeuN consisted of a biotinylated
horse anti-mouse IgG. The sections were incubated in a mix-
ture of secondary antibodies for BrdU and NeuN for 1 h,
rinsed in 0.1M PBS, and then incubated for a further 1 h in
streptavidin-549 to amplify the NeuN signal.
Double labelling using chicken anti-GFP and rabbit anti-Ki-67
Sections were double-labelled using the primary anti-
bodies chicken anti-GFP and rabbit anti-Ki-67 over a
two-day period. Sections on the slides were circled with
a wax pen and rinsed three times in 0.1 M PBS for
10 min each time. 0.1 M PBS containing 10% goat serum
and 0.3% triton-X100 was then added to each section
and incubated for 30 min at room temperature. Follow-
ing another brief wash in 0.1 M PBS, sections were
incubated overnight at 4°C with a mixture of rabbit anti-
Ki-67 and chicken anti-GFP antibodies diluted in 0.1M
PBS containing 5% goat serum and 0.25% triton X100.
Sections were then rinsed (3 x 10 min in 0.1M PBS) and
incubated for 3 h at room temperature with a mixture of
the secondary antibodies goat anti rabbit IgG and goat
anti-chicken IgG diluted in 0.1 M PBS containing 5%
goat serum and 0.25% triton X100. Sections were then
rinsed in 0.1M PBS (3 × 10 min), coverslipped with
fluorescent mounting medium and allowed to dry.
Fluorescence microscopy
An epifluorescence microscope (Leica DMLB2) and a con-
focal microscope (Olympus FV 1000) were used to visualize
the results of immunohistochemical staining. In the case of
epifluorescence microscopy, a HC software package was
used to capture images of the right hemisphere of the brain
at an objective lens magnification of X20. Images captured
under blue excitation (for green emission) and green excita-
tion (for red emission) wavelengths were merged to indicate
the presence of double-labelled (yellow) cells. In the case of
confocal microscopy, an FV software package was used to
capture images at X20 and X60 objective lens magnifica-
tions, and Z stacks were used to confirm double labelling.
Image analysis and cell counting
Images captured with the epifluorescence microscope,
and the associated merged images, were opened as TIFF
files using the Image Pro Plus 3DS software package. Using
the Media Cybernetics program, single-labelled (green or
red) and double-labelled (yellow) cells were manually
tagged and counted at various levels between 1.18 mm
and −0.46 mm from the bregma point, which spans much
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of the striatum, with the observer blinded to genotype.
We quantified cell numbers in the M1 region of the cor-
tex, the dorsal striatum and the periventricular region
[53]. The cell numbers were calculated for each of the five
pre-determined coronal bregma levels and all counts were
performed at the same magnification. Specifically, we
quantified cells in the dorsal striatum, which is located
ventral to the corpus callosum, with a counting frame
measuring 492μm in width and 375μm in height. The
counting frame extended ventrally from the junction of
the corpus callosum and the striatum. For analysis of the
periventricular region, the height of the counting frame
was 375μm and the width of the counting frame extended
across a distance of 300μm into the striatum from the
junction of the striatum and the lateral ventricular wall
(in the case of Ki-67+ cells) and across a distance of
300μm taken 150μm on either side of the midpoint of
the lateral ventricle (for quantification of periventricular
BrdU+ cells). This approach captured BrdU+ cells on
either side of the ventricle and within the highly proli-
ferative zone of the septal region. For analysis of the peri-
ventricular region, the counting frame was placed immediately
ventral of a cell dense dorsomedial region of the striatum that
is generally devoid of fibre bundles. We know that this part of
the striatum is relatively spared in the striatal model (see Add-
itional file 1: Figure S1). These data are presented either as
counts at specific bregma levels for different regions (cortex,
striatum or periventricular region) (Figures 3 and 6) or as cu-
mulative counts in which counts at multiple bregma levels are
summed for a given region (Figure 2).
As GFP expressing reporter mice were used in this
study, it is important to point out, for a number of rea-
sons, that BrdU+ cell counts (determined using green
fluorescence) obtained in mice carrying the Drd1a-EGFP
BAC transgene reflect the number of cells expressing
BrdU and not the number of GFP-expressing cells. First,
in our hands, green fluorescence related directly to ex-
pression of the Drd1a-EGFP BAC transgene is not ap-
parent without the use of an anti-GFP antibody. Second,
the cellular pattern of Drd1a-GFP and BrdU expression
is different (compare panels A-L in Figure 1 with panels
B-D and F-H in Figures 8). GFP expression (when detected
using anti-GFP immunofluorescence) involves the neuropil
and demarcates the entire neuronal cell, as the GFP protein is
present throughout the cytoplasm whereas BrdU is exclusively
nuclear. Third, reporter mice (i.e. Drd1a-GFP BAC transgene
expressing littermates) were used as controls in this experi-
ment. If we were counting GFP expressing cells then there
would be higher cell counts throughout the brain (identical to
what is seen in Figure 8) that would almost certainly swamp
any genotype specific BrdU signal, indeed, the number would
be greater in GFP-control mice as they have a greater number
of GFP expressing cells. Fourth, we are unable to identify GFP
expression in the cortex of Drd1a-EGFP BAC transgene
expressing reporter mice despite deploying anti-GFP anti-
body (presumably because of the low Drd1a-GFP level of
expression in this subpopulation) whereas BrdU-expressing
cells are readily apparent (see Figures 1A, D, E, H).
Statistics
Statistical analysis of the numbers of single-labelled and
double-labelled cells was performed using the GraphPadR
Prism software program, version 5.00 (GraphPadR Soft-
ware Inc., San Diego, CA, USA). Data were expressed as
mean ± standard error of the mean (SEM). A two-way
analysis of variance (ANOVA) was used to assess compari-
sons, the two variables being genotype and bregma level.
A Bonferroni post-hoc test was used if appropriate. Com-
parisons were deemed significant at P < 0.05.
Additional file
Additional file 1: Figure S1. Fluorescence microscopy highlighting
densely packed Drd1a-GFP-positive cells in the dorsomedial striatum.
Photomicrograph of striatal line Drd1a-GFP WT control mouse brain
(GFP cells labeled green) (A) and striatal line mutant mice on a GFP
genetic background (B). Drd1a-GFP-positive cells are abundantly
expressed throughout the striatum in the GFP-control mouse brain and
significantly lost in GFP-striatal mouse brain. Dotted line outlines the
dorsomedial striatum that remains relatively densely packed with
Drd1a-GFP-positive cells in both lines. Scale bar = 100 μm.
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